Hoffman, Ronald · Seminars in oncology · 2002 · DOI
This article discusses how doctors should measure quality of life in patients with two rare blood disorders (essential thrombocythemia and polycythemia vera). The author explains that while treatments can control blood cell production and prevent some serious complications, they often cause side effects. The article suggests that doctors should use quality-of-life questionnaires to better understand whether treatments are truly helping patients feel better overall.
This editorial is relevant to ME/CFS because both conditions involve chronic, progressive disease where treatment side effects significantly impact daily functioning. Like ME/CFS, these disorders require balancing symptom management against treatment toxicity, making quality-of-life assessment critical for patient-centered care. The editorial's emphasis on systematically measuring functional capacity and symptom burden reflects principles increasingly recognized as essential in chronic illness research.
This is an editorial opinion, not an empirical research study, so it does not provide data about actual quality-of-life outcomes or treatment efficacy. It does not establish that quality-of-life instruments would actually improve clinical decision-making in these disorders. The editorial makes no claims about ME/CFS specifically and should not be interpreted as evidence applicable to post-viral fatigue conditions.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →